Payment overview · 2025
General Payments
$430.54
15 reported records · 6 companies
Healthcare provider profile · identity verified
Olabode Olumofin, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · PINE BLUFF, AR · NPI 1720025513
Verified facts
What the public records show
CMS Open Payments records show Olabode Olumofin, M.D. received $430.54 in general payments during 2025 across 15 reported records.
ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) accounted for 32.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 6 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Verquvo.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 97 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Vraylar by this doctor in 2024.
Merck Sharp & Dohme LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VERQUVO as an associated drug or biological on 38060 records involving 12268 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Verquvo by this doctor in 2024.
SANOFI-AVENTIS U.S. LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LANTUS as an associated drug or biological on 12 records involving 11 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Lantus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $138.59 | 32.2% | 8 | 2025 |
| SANOFI-AVENTIS U.S. LLC | Unresolved — no canonical attribution shown | $76.82 | 17.8% | 1 | 2025 |
| ViiV Healthcare Company | Unresolved — no canonical attribution shown | $75.80 | 17.6% | 1 | 2025 |
| VERTEX PHARMACEUTICALS INCORPORATED | Unresolved — no canonical attribution shown | $70.28 | 16.3% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $51.26 | 11.9% | 3 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $17.79 | 4.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $430.54 | 15 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $138.59 | 8 | 2025 |
Source payment records
|
|||||
| TZIELD Normalized: tzield |
Biological | SANOFI-AVENTIS U.S. LLC | $76.82 | 1 | 2025 |
Source payment records
|
|||||
| APRETUDE Normalized: apretude |
Drug | ViiV Healthcare Company | $75.80 | 1 | 2025 |
Source payment records
|
|||||
| VERQUVO Normalized: verquvo |
Drug | Merck Sharp & Dohme LLC | $51.26 | 3 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $17.79 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $17.79 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| VERQUVO verquvo |
2025 | Verquvo | 2024 | 16 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
97 | 23 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Merck Sharp & Dohme LLC Exact reporting entity; no affiliate inference |
2025 | VERQUVO open payments reported associated product |
CMS Open Payments — General Payments 38060 supporting records · 12268 recipient NPIs · example record 1237992208 |
Verquvo · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| SANOFI-AVENTIS U.S. LLC Exact reporting entity; no affiliate inference |
2025 | LANTUS open payments reported associated product |
CMS Open Payments — General Payments 12 supporting records · 11 recipient NPIs · example record 1233196856 |
Lantus · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 1136 | 133 |
| Gabapentin | Gabapentin | 923 | 187 |
| Amlodipine Besylate | Amlodipine Besylate | 655 | 138 |
| Metoprolol Tartrate | Metoprolol Tartrate | 482 | 112 |
| Tizanidine Hcl | Tizanidine Hcl | 472 | 110 |
| Losartan Potassium | Losartan Potassium | 417 | 91 |
| Pravastatin Sodium | Pravastatin Sodium | 397 | 88 |
| Pantoprazole Sodium | Pantoprazole Sodium | 380 | 94 |
| Alprazolam | Alprazolam | 358 | 41 |
| Furosemide | Furosemide | 352 | 86 |
| Potassium Chloride | Potassium Chloride | 326 | 74 |
| Famotidine | Famotidine | 317 | 93 |
| Metformin Hcl | Metformin Hcl | 316 | 74 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 309 | 72 |
| Allopurinol | Allopurinol | 285 | 61 |
| Atorvastatin Calcium | Atorvastatin Calcium | 279 | 74 |
| Tamsulosin Hcl | Tamsulosin Hcl | 248 | 60 |
| Hydrochlorothiazide | Hydrochlorothiazide | 229 | 61 |
| Omeprazole | Omeprazole | 226 | 53 |
| Montelukast Sodium | Montelukast Sodium | 217 | 53 |
| Eliquis | Apixaban | 204 | 43 |
| Lisinopril | Lisinopril | 204 | 44 |
| Ozempic | Semaglutide | 195 | 34 |
| Carvedilol | Carvedilol | 192 | 42 |
| Xarelto | Rivaroxaban | 186 | 39 |
| Nifedipine Er | Nifedipine | 184 | 34 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 176 | 16 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 176 | 42 |
| Diclofenac Sodium | Diclofenac Sodium | 170 | 72 |
| Clopidogrel | Clopidogrel Bisulfate | 168 | 32 |
| Metoprolol Succinate | Metoprolol Succinate | 164 | 38 |
| Citalopram Hbr | Citalopram Hydrobromide | 158 | 34 |
| Duloxetine Hcl | Duloxetine Hcl | 142 | 21 |
| Levothyroxine Sodium | Levothyroxine Sodium | 142 | 29 |
| Lidocaine | Lidocaine | 139 | 65 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 136 | 27 |
| Glimepiride | Glimepiride | 133 | 27 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 133 | 47 |
| Oxycodone Hcl | Oxycodone Hcl | 132 | 16 |
| Sucralfate | Sucralfate | 123 | 33 |
| Estradiol | Estradiol | 119 | 20 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 119 | 24 |
| Tradjenta | Linagliptin | 119 | 29 |
| Prednisone | Prednisone | 118 | 32 |
| Pregabalin | Pregabalin | 116 | 28 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 116 | 27 |
| Hydralazine Hcl | Hydralazine Hcl | 113 | 36 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 113 | 25 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 108 | 21 |
| Clotrimazole | Clotrimazole | 98 | 50 |
| Linzess | Linaclotide | 97 | 23 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 97 | 20 |
| Spironolactone | Spironolactone | 97 | 23 |
| Mounjaro | Tirzepatide | 94 | 11 |
| Mirtazapine | Mirtazapine | 93 | 15 |
| Simvastatin | Simvastatin | 93 | 20 |
| Donepezil Hcl | Donepezil Hcl | 88 | 22 |
| Topiramate | Topiramate | 88 | 14 |
| Entresto | Sacubitril/Valsartan | 86 | 16 |
| Farxiga | Dapagliflozin Propanediol | 84 | 19 |
| Aripiprazole | Aripiprazole | 83 | 11 |
| Ibuprofen | Ibuprofen | 81 | 24 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 80 | 58 |
| Ezetimibe | Ezetimibe | 76 | 14 |
| Clonazepam | Clonazepam | 73 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 68 | 19 |
| Trazodone Hcl | Trazodone Hcl | 68 | 11 |
| Buspirone Hcl | Buspirone Hcl | 65 | 16 |
| Quetiapine Fumarate | Quetiapine Fumarate | 65 | suppressed |
| Fluconazole | Fluconazole | 63 | 30 |
| Promethazine Hcl | Promethazine Hcl | 63 | 17 |
| Symbicort | Budesonide/Formoterol Fumarate | 63 | 18 |
| Jardiance | Empagliflozin | 61 | 11 |
| Sertraline Hcl | Sertraline Hcl | 60 | 16 |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 56 | 38 |
| Fluticasone Propionate | Fluticasone Propionate | 56 | 16 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 56 | 16 |
| Colchicine | Colchicine | 54 | 14 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 54 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 54 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 53 | 18 |
| Amoxicillin | Amoxicillin | 50 | 23 |
| Metoclopramide Hcl | Metoclopramide Hcl | 50 | 11 |
| Zolpidem Tartrate | Zolpidem Tartrate | 50 | suppressed |
| Lorazepam | Lorazepam | 48 | 12 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 48 | 12 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 43 | 11 |
| Azithromycin | Azithromycin | 43 | 35 |
| Baclofen | Baclofen | 43 | suppressed |
| Bumetanide | Bumetanide | 42 | suppressed |
| Levetiracetam | Levetiracetam | 42 | 11 |
| Acyclovir | Acyclovir | 41 | 23 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 41 | 28 |
| Metronidazole | Metronidazole | 41 | 19 |
| Prazosin Hcl | Prazosin Hcl | 41 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 41 | 13 |
| Fluoxetine Hcl | Fluoxetine Hcl | 40 | suppressed |
| Meloxicam | Meloxicam | 40 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 38 | suppressed |
| Ranolazine Er | Ranolazine | 38 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 37 | suppressed |
| Glipizide | Glipizide | 36 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 36 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 35 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 34 | 19 |
| Trulicity | Dulaglutide | 34 | suppressed |
| Acetazolamide | Acetazolamide | 32 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 32 | 11 |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 31 | suppressed |
| Savella | Milnacipran Hcl | 30 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 30 | 12 |
| Gemfibrozil | Gemfibrozil | 29 | suppressed |
| Glyxambi | Empagliflozin/Linagliptin | 29 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 29 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 29 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 28 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 27 | suppressed |
| Digoxin | Digoxin | 27 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 26 | suppressed |
| Metolazone | Metolazone | 26 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 26 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 24 | suppressed |
| Ketoconazole | Ketoconazole | 24 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 23 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 23 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 23 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 22 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 22 | suppressed |
| Finasteride | Finasteride | 21 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 21 | suppressed |
| Nystatin | Nystatin | 21 | 13 |
| Ziprasidone Hcl | Ziprasidone Hcl | 21 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 20 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 20 | 17 |
| Megestrol Acetate | Megestrol Acetate | 20 | suppressed |
| Tobramycin | Tobramycin | 20 | 17 |
| Lansoprazole | Lansoprazole | 19 | suppressed |
| Nitroglycerin | Nitroglycerin | 19 | suppressed |
| Methimazole | Methimazole | 18 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 18 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 18 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 17 | suppressed |
| Verapamil Er | Verapamil Hcl | 17 | suppressed |
| Atenolol | Atenolol | 16 | suppressed |
| Levofloxacin | Levofloxacin | 16 | 12 |
| Memantine Hcl | Memantine Hcl | 16 | suppressed |
| Novolog Flexpen | Insulin Aspart | 16 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 16 | suppressed |
| Verquvo | Vericiguat | 16 | suppressed |
| Brilinta | Ticagrelor | 15 | suppressed |
| Buprenorphine-Naloxone | Buprenorphine Hcl/Naloxone Hcl | 15 | suppressed |
| Celecoxib | Celecoxib | 15 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 15 | 11 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 15 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 15 | suppressed |
| Lovastatin | Lovastatin | 15 | suppressed |
| Bupropion Xl | Bupropion Hcl | 14 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 14 | 13 |
| Fenofibrate | Fenofibrate,micronized | 14 | suppressed |
| Hydrocodone-Ibuprofen | Hydrocodone/Ibuprofen | 14 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 14 | suppressed |
| Methotrexate | Methotrexate Sodium | 14 | suppressed |
| Dilt-Xr | Diltiazem Hcl | 13 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 13 | suppressed |
| Valsartan | Valsartan | 13 | suppressed |
| Vraylar | Cariprazine Hcl | 13 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 12 | suppressed |
| Betamethasone Valerate | Betamethasone Valerate | 12 | suppressed |
| Lactulose | Lactulose | 12 | suppressed |
| Naproxen | Naproxen | 12 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 12 | suppressed |
| Carisoprodol | Carisoprodol | 11 | suppressed |
| Januvia | Sitagliptin Phosphate | 11 | suppressed |
| Medroxyprogesterone Acetate | Medroxyprogesterone Acetate | 11 | suppressed |
| Novolin R | Insulin Regular, Human | 11 | suppressed |
| Torsemide | Torsemide | 11 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $430.54 · 15 records | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | APRETUDE, CAPLYTA, QULIPTA, TZIELD, UBRELVY, VERQUVO | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Verquvo play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error